The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

National Psychopharmacology Update (Nevada Psychiatric Association)
February 11th – 14th 2026, Las Vegas, Nevada
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Bipolar Disorder
Schizophrenia
ENCORE POSTER
Olanzapine and Samidorphan in Adults With Schizophrenia or Bipolar I Disorder: Updated Review of Clinical Data
AUTHOR(S)

Leslie Citrome, MD, MPH,1 Christoph U. Correll, MD,2-6 Roger S. McIntyre, MD,7 Mark S. Todtenkopf, PhD,8 Christina Arevalo, MS,8 James A. McGrory, PhD,8 David McDonnell, MD9

Embargo date: 02-12-2026 Embargo time: 17:45 PST
Bipolar Disorder
Schizophrenia
Bipolar Disorder
Schizophrenia
ENCORE POSTER
Importance of Real-World Evidence in Clinical Decision-Making
AUTHOR(S)

Rakesh Jain, MD,1 Craig Chepke, MD,2 Andrew J. Cutler, MD,3,4 Hemangi R. Panchmatia, MSc,5 Michael J. Doane, PhD,5 Dennis Fried, PhD, MPH, MBA5 Madé Wenten, PhD, MPH,5 Barry Lubarsky, PhD5

Embargo date: 02-12-2026 Embargo time: 17:45 PST
Bipolar Disorder
Schizophrenia